These Growth Stocks Could Surge With a New NAFTA Deal

Pharmaceutical companies such as Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME) could benefit from a new NAFTA deal that includes longer data protection for biologic drugs.

| More on:

As NAFTA talks continue this week, investors have been trying to position themselves to capitalize on the inevitable changes to the tripartite pact. So far, the potential impact on the automotive and dairy industries have dominated headlines, but a renegotiated deal could also have significantly implications for the pharmaceutical industry.

It has been reported that the U.S. is seeking longer data protection for a class of drugs called “biologics.” A longer period of protection means that a generic drug maker would have to wait longer before it can introduce a competing biologic drug into the marketplace.

Biologics are drugs that are composed of or derived from biological molecules, cells, or tissues. Current protection for this class of drugs is eight years, but it has been reported that the U.S. wants this extended to 10 years.

The market for biologic drugs is huge. According to a 2017 report by the Patented Medicine Prices Review Board (PMPRB), a Canadian government agency that regulates the prices of patented medicines, biologic drug sales in Canada totaled $7 billion in 2017.

Furthermore, as stated in the PMPRB report, the market share (by revenue) of biologic drugs is on the rise; it has increased from 16% in 2009 to 42% in 2017.

As you can imagine, pharmaceutical companies are lobbying hard for longer biologic drug data protection, which would help to offset increasing R&D costs and boost profit.

Two Canadian pharmaceutical companies that would benefit from longer biologic drug patent protection are Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME) and Prometic Life Sciences Inc. (TSX:PLI).

Zymeworks is a Vancouver-based clinical-stage biopharmaceutical company that develops and commercializes multifunctional biotherapeutic drugs. The company’s revenue, which has grown by an impressive compound annual growth rate (CAGR) of 126% over the last four years, was US$51.8 million in 2017. The company reported a net loss of US$10.4 in 2017, which was an improvement from its reported net loss of US$33.8 million in 2016.

In the second quarter of this year, Zymeworks reported revenue of US$22 million and a net loss of US$5.9 million, which were an improvement over its reported revenue of US$1.3 million and net loss of US$11 million in the corresponding period last year.

Prometic Life Sciences is a Laval-based biopharmaceutical corporation that specializes in drug discovery for the treatment of rare and orphaned diseases and in the purification of biopharmaceuticals from human plasma. Revenue, which reached $39.1 million in 2017, has increased by a CAGR of 13% since 2013. Prometic reported a loss of $109.7 million in 2017, slightly more than the reported $100.8 million loss in 2016.

Prometic’s second-quarter revenue increased from $3.6 million in 2017 to $20.2 million in 2018. The company’s 2018 second-quarter net loss of $33.1 million was slightly higher than the net loss of $31.5 million it reported for the corresponding period last year.

Investor takeaway

NAFTA negotiations are still ongoing, and it is likely that Canada will object to the proposed increase in data protection for biologic drugs over fears that it will dramatically increase healthcare costs.

However, Canada will undoubtedly have to compromise in order to get the NAFTA deal done. Will patent protection for biologics be one area of compromise? Investors should keep their ears to the ground and their eyes on Zymeworks and Prometic Life Sciences.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Kenrick Vassall has no position in any of the stocks mentioned.

More on Investing

Sliced pumpkin pie
Dividend Stocks

2 Delicious Dividend Stocks I Plan to Add to My TFSA in October

These dreamy dividend stocks can provide you with endless dividends in your TFSA. And it's why I'm considering them right…

Read more »

The letters AI glowing on a circuit board processor.
Tech Stocks

Is Nvidia’s Growth Sustainable?

Nvidia stock soars 1,069% in 2 years. Is this AI chip titan's growth sustainable, or are we witnessing a bubble…

Read more »

Canada day banner background design of flag
Investing

3 Growth Stocks to Buy Now and Hold Forever

These Canadian growth stocks have delivered stellar returns but still have room for growth and can deliver solid capital gains…

Read more »

Hand Protecting Senior Couple
Dividend Stocks

TFSA Pension: How Couples Can Earn $9,500 per Year in Tax-Free Passive Income

This investing strategy can reduce risk and boost returns.

Read more »

calculate and analyze stock
Investing

If You Had Invested $1,000 in Dollarama Stock 5 Years Ago, This Is How Much You’d Have Now

As Dollarama's share price consistently grows year over year, here's how much long-term investors are making owning the top stock.

Read more »

shopper buys items in bulk
Dividend Stocks

9.9% Dividend Yield? I’ll Be Buying This TSX Passive-Income Stock in Bulk

Why make investing complicated? This ETF makes earning monthly income easy.

Read more »

worker holds seedling in soybean field
Investing

Got $10,000? Here’s How It Could Become $100,000

Investing in smart small cap-stocks could be a faster way to multiply your wealth.

Read more »

Canadian dollars in a magnifying glass
Investing

2 High-Yield Dividend ETFs to Buy to Generate Passive Income

These two high-yield Hamilton ETFs pay monthly and offer exposure to real assets.

Read more »